D M Eccles1, N Li2, R Handwerker3, T Maishman3, E R Copson3, L T Durcan3, S M Gerty3, L Jones4, D G Evans5, L Haywood4, I Campbell6. 1. Faculty of Medicine and Cancer Sciences, University of Southampton, Southampton, UK d.m.eccles@soton.ac.uk. 2. Cancer Genetics Laboratory, Peter MacCallum Cancer Centre, East Melbourne, Australia Cancer Biology Research Center Tongji Hospital, Huazhong University of Science and Technology, Wuhan, China. 3. Faculty of Medicine and Cancer Sciences, University of Southampton, Southampton, UK. 4. Barts Cancer Institute (CRUK) and Centre for Tumour Biology, Queen Mary University of London, London. 5. Genomic Medicine Institute of Human Development, University of Manchester and St Mary's Hospital, Manchester, UK. 6. Cancer Genetics Laboratory, Peter MacCallum Cancer Centre, East Melbourne, Australia Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia.
Abstract
BACKGROUND: Young age at diagnosis for breast cancer raises the question of genetic susceptibility. We explored breast cancer susceptibility genes testing on ≤40-year-old patients with HER2-amplified invasive breast cancer. PATIENTS AND METHODS: Patients were selected from a large UK cohort study. The inclusion criterion was age ≤40 at diagnosis with confirmed HER2-amplified breast cancer. The probability of finding a BRCA gene mutation was calculated based on family history. Genetic testing used was either clinical testing for BRCA1 and BRCA2, with a subset also tested for TP53 mutations, or research-based testing using a typical panel comprising 17 breast cancer susceptibility genes (CSGs) including BRCA1, BRCA2 and TP53. RESULTS: Of the 591 eligible patients, clinical testing results were available for 133 cases and an additional 263 cases had panel testing results. BRCA testing across 396 cases found 8 BRCA2 (2%) and 6 BRCA1 (2%) pathogenic mutations. Of the 304 patients tested for TP53 mutations, overall 9 (3%) had deleterious TP53 mutations. Of the 396 patients, 101 (26%) met clinical criteria for BRCA testing (≥10% probability), among whom 11% had pathogenic BRCA mutations (6 BRCA2, 5 BRCA1). Where the probability was calculated to be <10%, only 4 of 295 (1%) patients had BRCA mutations. Among the 59 patients who had TP53 testing meeting the 10% threshold, 7 had mutations (12%). Likely functionally deleterious mutations in 14 lower penetrance CSGs were present in 12 of 263 (5%) panel-tested patients. CONCLUSION: Patients aged <41 at diagnosis with HER2+ breast cancer and no family history of breast cancer can be reassured that they have a low chance of being a high-risk gene carrier. If there is a strong family history, not only BRCA but also TP53 gene testing should be considered. The clinical utility of testing lower penetrance CSGs remains unclear.
BACKGROUND: Young age at diagnosis for breast cancer raises the question of genetic susceptibility. We explored breast cancer susceptibility genes testing on ≤40-year-old patients with HER2-amplified invasive breast cancer. PATIENTS AND METHODS: Patients were selected from a large UK cohort study. The inclusion criterion was age ≤40 at diagnosis with confirmed HER2-amplified breast cancer. The probability of finding a BRCA gene mutation was calculated based on family history. Genetic testing used was either clinical testing for BRCA1 and BRCA2, with a subset also tested for TP53 mutations, or research-based testing using a typical panel comprising 17 breast cancer susceptibility genes (CSGs) including BRCA1, BRCA2 and TP53. RESULTS: Of the 591 eligible patients, clinical testing results were available for 133 cases and an additional 263 cases had panel testing results. BRCA testing across 396 cases found 8 BRCA2 (2%) and 6 BRCA1 (2%) pathogenic mutations. Of the 304 patients tested for TP53 mutations, overall 9 (3%) had deleterious TP53 mutations. Of the 396 patients, 101 (26%) met clinical criteria for BRCA testing (≥10% probability), among whom 11% had pathogenic BRCA mutations (6 BRCA2, 5 BRCA1). Where the probability was calculated to be <10%, only 4 of 295 (1%) patients had BRCA mutations. Among the 59 patients who had TP53 testing meeting the 10% threshold, 7 had mutations (12%). Likely functionally deleterious mutations in 14 lower penetrance CSGs were present in 12 of 263 (5%) panel-tested patients. CONCLUSION:Patients aged <41 at diagnosis with HER2+ breast cancer and no family history of breast cancer can be reassured that they have a low chance of being a high-risk gene carrier. If there is a strong family history, not only BRCA but also TP53 gene testing should be considered. The clinical utility of testing lower penetrance CSGs remains unclear.
Authors: J J Bakhuizen; F B Hogervorst; M E Velthuizen; M W Ruijs; K van Engelen; T A van Os; J J Gille; M Collée; A M van den Ouweland; C J van Asperen; C M Kets; A R Mensenkamp; E M Leter; M J Blok; M M de Jong; M G Ausems Journal: Fam Cancer Date: 2019-04 Impact factor: 2.375
Authors: Emilia Rogoża-Janiszewska; Karolina Malińska; Bohdan Górski; Rodney J Scott; Cezary Cybulski; Wojciech Kluźniak; Marcin Lener; Anna Jakubowska; Jacek Gronwald; Tomasz Huzarski; Jan Lubiński; Tadeusz Dębniak Journal: Breast Cancer Date: 2020-09-04 Impact factor: 4.239
Authors: Carla Escudeiro; Carla Pinto; Joana Vieira; Ana Peixoto; Pedro Pinto; Manuela Pinheiro; Catarina Santos; Joana Guerra; Susana Lisboa; Rui Santos; João Silva; Conceição Leal; Nuno Coimbra; Paula Lopes; Marco Ferreira; Ana B Sousa; Manuel R Teixeira Journal: Fam Cancer Date: 2020-10-14 Impact factor: 2.375
Authors: Cristina Fortuno; Jessica Mester; Tina Pesaran; Jeffrey N Weitzel; Jill Dolinsky; Amal Yussuf; Kelly McGoldrick; Judy E Garber; Sharon A Savage; Payal P Khincha; D Gareth Evans; Maria Isabel Achatz; Kim E Nichols; Kara N Maxwell; Joshua D Schiffman; Renata Sandoval; Paul A James; Amanda B Spurdle Journal: Hum Mutat Date: 2020-06-12 Impact factor: 4.700